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The Fanconi gene family has a role in DNA repair and inactivation of FANCF has been proposed as a mechanism of sensitisation to
platinum chemotherapy. This study sought to confirm this hypothesis in cell lines and a large series of ovarian cancer samples.
Promoter methylation was assessed by methylation-sensitive polymerase chain reaction of FANCF in nine ovarian cancer cell lines
and 74 ovarian cancer samples taken from patients entered on a trial of cisplatin-based chemotherapy. This study confirmed
methylation-dependent silencing of FANCF in one out of nine ovarian cancer cell lines. Methylation of FANCF was demonstrated
in 13.2% of 53 evaluable ovarian tumour samples. Progression-free survival gave an HR of 3.63 (95% CI: 1.54–8.54, P¼0.0016) in
favour of the unmethylated cases. There was no association with overall survival. This study does not support methylation-dependent
silencing of FANCF as a mechanism of sensitisation to platinum-based chemotherapy in ovarian cancer.
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Ovarian cancer is in many cases a chronic disease characterised by
protracted sensitivity to anticancer agents, of which the most
active are the platinum coordination complexes. These are thought
to lead to cell death through DNA cross-linking, causing
unrepairable DNA damage and activation of apoptosis. While the
majority of cases initially respond to the platinum compounds,
resistance eventually develops by mechanisms that remain poorly
defined (Shah and Schwartz, 2001). The Fanconi DNA repair
pathway protects cells against death and genotoxicity induced by
cross-linking agents, including cisplatin and the alkylating agents.
One function of the FANC proteins is to support the integrity of
the RAD51-, NBS1-, BRCA1- and BRCA2-dependent pathways for
DNA repair, and also suppressing apoptotic responses to
nonchemical extracellular signals (Bagby and Olson, 2003). Defects
in these proteins are associated with Fanconi anaemia, a syndrome
characterised by hypersensitivity to DNA cross-linking agents
(D’Andrea and Grompe, 2003). At least seven genes encoding
proteins participating in the Fanconi pathway have been identified.
These encode proteins that cooperate in a DNA damage response,
including FANCD1 (BRCA2).
Methylation-dependent transcriptional silencing of FANCF
occurs in cisplatin-sensitive epithelial ovarian cancer cell lines,
implying that platinum resistance correlates with the methylation
state of the CpG island of FANCF and suggesting a model of
reversible methylation of FANCF leading initially to chromosomal
instability associated with platinum sensitivity, followed by
demethylation and expansion of platinum-resistant clones
(Taniguchi et al, 2003). These authors found no mutation in the
FANCF gene, but methylation of the promoter region of FANCF in
4 out of 19 (21%) ovarian cancer samples. This finding was
subsequently confirmed by Wang et al (2006), who found
methylation in 5 out of 18 cases of ovarian cancer, but no study
has formally addressed the issue of whether loss of FANCF
function, via methylation-dependent silencing, influences clinical
outcome in patients treated with cisplatin. Here, we have analysed
the methylation status of the FANCF CpG island in a series of
ovarian cancer patients treated on a clinical trial to address the
possibility that methylation of FANCF is a determinant of clinical




The following epithelial ovarian cancer cell lines were used: 1847,
SKOV3, TR175, JAMA2, OVCAR3 and OVCA433. A2780 and its
cisplatin- and doxorubicin-resistant derivatives, A2780cis and
A2780adr, respectively, were obtained from the European Collec-
tion of Cell Cultures (ECACC). Cells were routinely grown in
DMEM supplemented with 10% fetal bovine serum. Drug
resistance of A2780cis and A2780adr was maintained by exposure
to each agent as recommended by the supplier. Primary, ovarian
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sgerminal epithelial cells were prepared and cultured as described
by Kruk et al (1990). Genomic DNA was prepared from
exponentially growing cells using proteinase K digestion and total
RNA using RNAzol B.
Ovarian cancer tissue samples
A single representative tissue block was obtained from 74 patients
entered on a randomised controlled trial carried out by the EORTC
(Study 55931). This randomised 640 patients with predominantly
stage III and IV disease to cisplatin (80mgm
 2) and cyclosphos-
phamide (800mgm
 2) (CP) or cisplatin (80mgm
 2)a n dp a c l i t a x e l
(175mgm
 2) (TP) over 3h for six cycles (Piccart et al, 2003). At a
median follow-up of 6.5 years, this study showed a
4-month improvement in survival in favour of the cisplatin/
paclitaxel arm (HR¼0.75, 95% CI: 0.63–0.90, P¼0.001). This
translational study was approved by the Wirral Research Ethics
Committee, UK. Ten-micron sections were cut for DNA extraction
and adjacent four-micron sections stained by H&E and immuno-
histochemistry. Genomic DNA was extracted from the single
10-mm tissue section using the Pinpoint DNA Isolation System TM
(Zymo Research, Cambridge, UK).
Analysis of FANCF expression and methylation
For analysis of FANCF mRNA expression in ovarian cancer cell
lines, 1mg total RNA was converted to first-strand cDNA using
M-MLV Reverse Transcriptase and the Oligo (dT)12–18 primer
(Invitrogen, Paisley, UK). Reverse transcription-polymerase chain
reaction (RT-PCR) primers were as follows: FANCF forward, 50-AG
GAGGACTCTCTGATGAAGACCC-30 and reverse, 50-CAGGTGATT
TGTGGATGCCG-30; and GAPDH forward, 50-TGAAGGTCGGAGT
CAACGGATTG-30 and reverse, 50-GCCATGAATTTGCCATGCCA
TGGGTGG-30.
Polymerase chain reaction was for 26 cycles for both FANCF and
GAPDH, after which reaction products were resolved on 2%
agarose gels.
Methylation in FANCF was analysed using methylation-sensitive
PCR (MSP) (Herman et al, 1996), using the primers and conditions
described by Taniguchi et al (2003). Briefly, 1mg of genomic DNA
was subjected to sodium bisulphite conversion using EZ DNA
Methylation Kit (Zymo Research). Control genomic DNAs were (i)
methylated human genomic DNA (Chemicon
s, Hampshire, UK)
and (ii) DNA isolated from the peripheral blood lymphocytes of
healthy individuals. Methylation-sensitive PCR was performed in a
reaction volume of 20ml for 38 cycles after which products were
resolved on 2% agarose gels and visualised under UV illumination
to compare unmethylated and methylated amplifications. Samples
were scored by visual comparison of unmethylated and methylated
reactions.
Each DNA was analysed a minimum of three times. Samples
were deemed positive if FANCF MSP primers were as follows:
methylated forward, 50-TTTTTGCGTTTGGAGAATCGGGTTTT
C-30 and reverse, 50-ATACACCGCAAACCGCCGACGAACAAA
ACG-30; unmethylated forward, 50-TTTTTGTGTTTGTTGGAGAA
TTGGGTTTTT-30 and reverse, 50-ATACACCACAAACCACCAACA
AACAAAACA-30.
Bisulphite sequencing was carried out using the following
primers: forward, 50-TTTTTGTTTTTATTGGTTGTGTAGT-30 and
reverse, 50-AAATCCCTTCTACAACACCTAAATC-30.
Polymerase chain reaction products were purified with a PCR
Purification Kit (Qiagen Ltd, West Sussex, UK), ligated into a TA
cloning vector (Invitrogen Ltd) and transformed into Top 10
Escherichia coli competent cells (Invitrogen Ltd). Colonies were
grown on LB-agar plates under ampicillin and blue/white selection.
Insert-containing colonies were cultured and plasmid DNA
isolated and used as template in a dideoxy cycle sequencing
reaction using the Big Dye Terminator Cycle Kit (PE Applied
Biosystems, Foster City, CA, USA) and reverse primers. For each
sample, a minimum of 12 clones were sequenced, to determine the
overall level of methylation within CpG islands.
Statistical analysis
Overall survival (OS) time and disease-free survival time were
defined as the period that elapsed from primary surgery to death
and to death or relapse, respectively. Kaplan–Meier analyses and
the log-rank test (Kaplan and Meier, 1958; Tarone and Ware, 1977)
were used to estimate and compare OS and disease-free survival
curves. The independent effects of prognostic factors and other
covariates on survival function were determined by the COX
proportional-hazards regression model, stratified for the assigned
treatment group (Cox, 1972). Correlations between various factors
were assessed by Spearman’s rank correlations. The proportiona-
lity assumptions of the method were tested graphically by looking
at the log-minus-log survival function plots. The stability of the
variables entered in the final model was examined by repeating
the analysis excluding each factor in turn.
RESULTS
FANCF methylation in epithelial ovarian cancer cell lines
We analysed methylation in the FANCF CpG island in a panel of
ovarian cancer cell lines. We detected no evidence of methylation
in 1847, SKOV3, TR175, JAMA2, OVCAR3, OVCA433, A2780 and
its cisplatin-resistant derivative A2780cis. However, methylation
was clearly and reproducibly detected in the doxorubicin-resistant
derivative A2780adr, while methylated and unmethylated controls
showed only appropriate amplified products (Figure 1A). To
confirm these results, we performed bisulphite sequencing of the
FANCF CpG island in A2780, A2780cis, A2780adr and in normal
ovarian germinal epithelium. These studies verified that methyla-
tion was not detectable in A2780, A2780cis or normal ovarian
epithelium, but was clearly present in A2780adr (Figure 1B). By
semiquantitative RT-PCR, FANCF mRNA was readily detected in
each of the cell lines, but was expressed at a very low level in
A2780adr, consistent with the presence of methylation (Figure 1C).
To verify that transcriptional downregulation was associated with
aberrant CpG methylation, A2780adr cells were treated with the
demethylating agent 5-azacytidine (AZA). The steady-state level of
FANCF mRNA was clearly upregulated by exposure to this agent
(Figure 1C), consistent with the hypothesis that aberrant methyla-
tion is the mechanistic basis for downregulation of the mRNA. In
additional analyses, we did not observe transcriptional down-
regulation of FANCA, FANCC, FANCD1, FANCD2, FANCE or
FANCG mRNA and found no evidence of methylation in the CpG
islands of any of these genes in our ovarian cancer cell line panel.
These results reveal downregulation of FANCF mRNA in the
doxorubicin-resistant A2780adr epithelial ovarian carcinoma cell
line and show that this correlates with aberrant CpG island
methylation.
Ovarian cancers
Using the same MSP primers, we next analysed methylation in the
FANCF CpG island (Figure 2) in the 74 patients. We reproducibly
detected methylation in seven (9.4%) cases. To confirm the
sensitivity and specificity of the MSP reaction conditions, we
performed bisulphite sequence analysis of cases classified as
positive or negative by MSP. There was no evidence of methylated
CpGs by bisulphite sequencing in case 26 (unmethylated by MSP),
but clear evidence in case 27 (methylated by MSP) (Figure 1C).
To assess whether the 74 patients in this study were
representative of the trial population, the patient characteristics
were compared with the other 317 patients randomised by EORTC
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sand NCIC centres, which contributed to the sample collection, and
no significant differences were observed. The median survival of
the 74 patients was 2.31 years (95% CI: 2.65–3.25) and 2.57 years
(95% CI: 2.17–2.97) in the other 317 randomised patients. Of the
67 FANCF patients negative for FANCF methylation, 31 were in the
CP and 36 in the TP arm. Of the seven positive patients, four were
on the CP arm and three received TP.
Table 1 shows the correlation with clinicopathological variables
in the series. Methylation of FANCF was seen more commonly in
85.7% of the serous subtypes compared with 65.7% of the
nonserous tumours but this was not significant (P¼0.32). There
was no association with age, stage, grade or residual tumour mass.
Methylation of FANCF was not observed in any of six normal
ovarian germinal epithelial preparations.
Analysis of response and FANCF status is limited by the small
numbers, and the number of categories requiring grouping of CR
(complete response), PR (partial response) SD (static disease),
NED (no evidence of disease after primary surgery), PD
(progressive disease) and NE (not evaluable). Across the whole
group, there was no association between response and FANCF
status (P¼0.331). In the 34 patients on the cisplatin/cyclophos-
phamide arm, methylation-negative status was associated with the
CRþPRþSD group compared with the PD category (P¼0.0098)
after exclusion of the nonevaluable cases (Table 2). No such
association was seen in the cisplatin/paclitaxel arm.
(Years)
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Figure 2 Kaplan–Meier curves for survival for 74 ovarian cancer patients
by FANCF methylation status (P¼0.0016). Uninformative cases shown as
false negative cases (dotted line). Methylation-positive cases are shown by
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Figure 1 Methylation analysis of the FANCF CpG island in epithelial
ovarian cancer. (A) Methylation-sensitive PCR analysis of the FANCF CpG
island in ovarian cancer cell lines. Methylation-sensitive PCR was performed
in the indicated cell lines as described in the Materials and Methods. For
each cell line, unmethylated (U) and methylated (M) reactions are shown.
Control unmethylated (CU) and methylated (CM) reactions are also shown.
(B) Bisulphite sequencing of part of the FANCF CpG island. The CpG sites
are shown as vertical lines on the top horizontal line. Methylated CpG sites
are shown as black blocks. Five levels of methylation are indicated: 0 – no
black blocks; 1–25% – one black block; 25–50% – two black blocks; 50–
75% – three black blocks; and 75–100% – four black blocks. (C) Reverse
transcription-polymerase chain reaction analysis of FANCF expression in
epithelial ovarian cancer cell lines. Reverse transcription-polymerase chain
reaction was performed in the indicated cell lines as described in the
Materials and Methods. In the case of A2780adr, reactivation of expression
by AZA is also shown. (D) Methylation analysis of the FANCF CpG island
in primary ovarian carcinomas. Methylation-sensitive PCR was performed in
the indicated cell lines as described in the Materials and Methods.
Methylation is readily detectable in cases T27 and T43. Control
unmethylated (CU) and methylated (CM) reactions are also shown.
Table 1 Relation of FANCF methylation status and clinicopathologic











64.1 (42.3–65.9) 59.3 (22.8–76.4) 0.937*
Age o65 3 (42.9%) 36 (53.7%) 0.701
Age 465 4 (57.1%) 31 (46.3%)
Performance status
0 2 (28.6%) 22 (47.8%) 0.688
1 3 (42.9%) 15 (32.6%)
2 2 (28.6%) 8 (17.4%)
3 0 (0%) 1 (2.2%)
Stage
IIB/IIC/III 5 (71.4%) 36 (78.3% 0.462
IV 2 (28.6%) 9 (19.6%)
Missing 0 (0%) 1 (2.1%)
Histology
Serous 6 (85.27%) 27(58.7%) 0.136
Nonserous 0 (0%) 12 (26.1%)




3 (42.9%) 21 (45.7%) 0.449
Poorly
differentiated
4 (57.1%) 18 (39.1%)
Missing 0 (0%) 87 (15.2%)
Residual tumour volume
o1cm 1 (14.3%) 13 (28.3%) 0.383
X1cm 6 (85.7%) 32 (69.6%)
Missing 0 (0%) 1 (2.1%)
*Mann–Whitney U-test (two-sided) P-value.
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sThe analysis of survival outcome was performed excluding
the 21 cases negative in both the U and M reactions, as these
are regarded as uninformative. On this basis, the proportion of
cases positive for methylation of FANCF becomes 13.4%.
Progression-free survival (PFS) gave an HR of 3.63 (95% CI:
1.54–8.54, P¼0.0016) in favour of the unmethylated cases as
shown in Figure 2. When adjusted for treatment, stage, residual
mass after surgery, WHO performance status and age in multi-
variate analysis, the HR was 3.7 (95% CI: 1.43–9.54, P¼0.001).
These data are consistent with an adverse outcome for methylated
cases when treated by platinum-based chemotherapy. For the
analysis of OS, the HR was 1.56 for FANCF-negative status (95%
CI: 0.65–3.74, P¼0.31). These values are not significant. When
adjusted for the same factors, the HR for OS fell to 1.162 (95% CI:
0.434–3.113, P¼0.77). There was no interaction between treat-
ment arm and either PFS or OS. Response was not associated with
survival.
Analysis of the PFS at greater or less than 10.5 months, a time
point chosen as treatment time on platinum-based chemotherapy
plus 6 months, to correspond with the generally accepted time
point to separate platinum-refractory/resistant patients from
sensitive patients Markman and Bookman (2000), shows that
FANCF methylated patients are 2.5 times more likely to have
progressed than FANCF unmethylated cases.
DISCUSSION
In this study, we have addressed the hypothesis that methylation-
dependent transcriptional silencing of FANCF is a determinant of
clinical response and outcome to platinum-based adjuvant
chemotherapy of epithelial ovarian cancer.
The original observations of Taniguchi et al (2003) suggested
that reduced expression of FANCF would be associated with
increased sensitivity to cisplatin based on studies on two cell lines
and a small number of clinical samples whose treatment or
outcome were not specified. In the present study, we have observed
FANCF methylation in one cell line, but failed to show methylation
by MSP and bisulphite sequencing in either the cisplatin-sensitive
A2780 or its derivative with acquired cisplatin resistance, A2780cis.
In contrast, FANCF mRNA levels were greatly reduced in the
doxorubicin-resistant A2780adr and this correlated with aberrant
methylation in the FANCF CpG island, as assessed by MSP and
bisulphite sequencing. The mechanistic association between
methylation and transcriptional downregulation was supported
by partial reactivation by AZA pretreatment, consistent with an
epigenetic mechanistic basis for silencing of the gene.
Our detection of methylation in the FANCF CpG island (9.4%) is
comparable to the frequencies reported by Taniguchi et al (2003)
and Wang et al (2006). A fourth study by Teodoridis et al (2005)
failed to detect FANCF methylation in 106 stage III and IV ovarian
cancers. It is unclear whether the differences between the studies
that are positive for methylation (including the present one) and
that of Teodoridis are due to differences in techniques or patient
populations. It should be noted that cases positive for methylation
by MSP in our series of patients were confirmed by bisulphite
sequencing, both in the A2780adr cell line and in primary ovarian
cancers. Furthermore, our data are broadly consistent with studies
of other cancer types. For example, methylation of FANCF has
been reported in 6.7% (4/60) testicular tumours Koul et al (2004),
15% (13/89) head and neck cancers (Marsit et al, 2004) and
30% (30/100) cervical cancers (Narayan et al, 2004). Moreover, in a
study of 158 cases of nonsmall cell lung cancer, Marsit et al (2004)
found 22 (14%) to have promoter methylation of FANCF, and
this was also associated with adverse survival (HR¼3.1, 95% CI:
1.2–7.9, P not reported).
In this series of patients treated on a clinical trial with
standardised treatment and follow-up, FANCF methylation was
an adverse prognostic factor, at least for PFS, and there was no
significant effect on survival. One arm was treated with cisplatin
and cyclophosphamide, both cross-linking agents, while the other
arm was treated with cisplatin plus a taxane, and even in the
former group treated with two cross-linking agents, after allowing
for the small numbers, the response data provide no evidence in
favour of FANCF methylation-sensitising patients to this che-
motherapy combination. It is therefore likely that FANCF
methylation is not a major feature of chemonaive ovarian cancers,
but may be a ‘progression factor’ occurring late in the process of
carcinogenesis. Furthermore, methylation of FANCF is unlikely to
have a major impact on response to established anticancer agents
in epithelial ovarian cancer.
One explanation of the disparity may lie in the relation-
ship between genotoxicity and apoptotic cell death. A cell
may suffer major genotoxic damage, which does not lead to
apoptosis as there are different pathways involved in
these processes (Bagby and Olson, 2003). The overall chemosensi-
tivity effect is likely to be due to the interaction of
multiple pathways subject to control by genetic and epigenetic
mechanisms. The extent to which these pathways are linked is
unknown in human tumours, and the therapeutic implications are
complex. For example, if the Taniguchi model were correct, the
predicted effect of the use of nonselective demethylating agents
would be to reactivate FANCF expression, and thereby increase
cellular resistance to cisplatin. Conversely, Gifford et al (2004)
have clearly shown that acquired methylation of hMLH1
is associated with clinical resistance to cisplatin-based
chemotherapy.
The inactivation of FANCF as a marker of platinum sensitivity
may be too simplistic, as Taniguchi et al concede in their
description of sequential changes in methylation status during the
life cycle of the tumours. It should also be pointed out that the
samples in this study were taken prior to cisplatin exposure, and
the methylation status of FANCF may have changed in some
patients after exposure. Repeat biopsy at relapse or progression
would be necessary to confirm this and determine the dynamics of
methylation, drug response and outcome. Alternatively, it may be
possible to detect methylated FANCF DNA in peripheral blood to
address this.
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Table 2 Response in 74 patients at the end of treatment (surgery and




(WHO) FANCF  FANCF+ FANCF  FANCF+
CR 8 (26.7) 0 7 (18.9) 1 (33.3)
PR 5 (26.7) 1 (25) 4 (10.8) 0
SD 1 (3.3) 0 2 (5.4) 1 (33.3)
NED 3 (10) 0 10 (27.0) 0
PD 2 (6.7) 3 (75) 3 (8.1) 0
Missing 1 (3.3) 0 0 0
NE 10 (33.3) 0 11 (29.7) 1 (33.3)
CR¼complete response; NE¼not evaluable; NED¼no evaluable disease;
PD¼progressive disease; PR¼partial response; SD¼static disease.
aAssociation
between negative FANCF status and response (CR+PR+SD vs PD, excluding NE and
NED) P¼0.0098. There was no correlation between response and methylation
status in the cisplatin and paclitaxel group (P¼0.5023).
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